Fichas
Chronic Asthma (Part 1)
Fichas del conjunto (29)
- 1Bronchial hyper responsiveness occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. None1. Both Early and Late phase
2. Chronic phase
*** All phases listed here
*** Allergens trigger hyper responsiveness - 2Tracheal constriction occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. None1. Could be all phases (F) and could be none (G)
2. Explanation: Tracheal constriction is not as important in asthma, b/c they aren’t that viable in asthma. - 3Allergens bind to IgE antibodies occur at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. NoneEarly phase
- 4Vasodilation occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. None1. Both Early and Late phase
2. not all phases bc chronic remodel airway (scarring) and replace with connective tissues… so no vasodilation. - 5Bronchospasm occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. NoneAll phases
- 6Type I cell injury occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. NoneBoth Early and Late phase
- 7Increased mucus secretion occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. NoneAll phases
*** bc goblet cells are located in the trachea and bronchi - 8Smooth muscle proliferation occurs at A. Early B. Late C. Chronic D. Both A/B E. Both B/C F. All phases G. NoneChronic phase
- 9What is the 1st Cytokines released a. Eosinophil b. Basophil c. T2H d. NeutrophilNeutrophil
- 10What are the Leukotrienes released? a. Eosinophil b. Basophil c. T2H d. NeutrophilEosinophil
T2H cells - 11Which of the following may result in chronic airway inflammation and remodeling? a. Leukocyte activation b. Smooth muscle hypertrophy c. Mucous production d. Leukotriene productionLeukocyte activation
- 12What pathogenetic mechanisms are responsible for a patient’s symptoms of wheezing, shortness of breath, and chest tightness? a. Airway inflammation b. Low perfusion of oxygen c. Anxiety d. Respiratory infectionAirway inflammation
- 13Which of these is true? 1. The smaller the particle size, the greater the chance the particles will get absorbed and will be in the alveoli 2. larger particles will not be able to get to the alveoli, so it will get to the throat1. True
2. True - 14What is the role of LOX- 5?Activation of 5-LOX stimulates production of leukotrienes that promote bronchoconstriction and inflammation
- 15What are the snxs of intermittent asthma attack?1. Daytime snxs not more than 2 days/wk
2. Nocturnal snxs not more than 2 times /mo
3. Use of short acting B-agonist inhaler for snxs control not more than 2 days /wk.
4. Asthma does not interfere w/ normal activity
5. 0 - 1 execration that requires oral systemic corticosteroids per year. - 16What are the lung fnx snxs of intermittent asthma attack?1. Normal FEV1 btw exacerbation FEV1 =/>80%
2. FEV1/FVC normal - 17What are the snxs of mild persistent asthma attack?1. Daytime snxs > 2 days/week but not daily
2. Nocturmal snxs > 3-4 times/month
3. Use of inhaled short-acting B-agonists for snx control > 2 days/week but not greater than 1 time per day.
4. Minor limitations of normal activity =/> 2 exacerbations requiring oral systemic corticosteroids per year. - 18What are the lung fnx snxs of mild persistent asthma attack?FEV1 =/> 80%
FEV1/FVC normal - 19What are the snxs of moderate persistent asthma attack?1. Daily snxs
2. Nocturnal snxs > 1x/wk but not every night
3. Daily use of inhaler, short acting B-agonists
4. Some limitation of normal activity - 20What are the lung fnx snxs of moderate persistent asthma attack?FEV1 60 - 79%
FEV1/FVC reduced by 5% - 21What are the snxs of severe persistent asthma attack?1. Snxs occur throughout the day.
2. Nocturnal snxs every night
3. Use of inhaled, short-acting B-agonists several times per day
4. Extremely limited normal activity - 22What are the lung fnx snxs of severe persistent asthma attack?FEV1 < 60%
FEV1/FVC reduced by greater than 5% - 23Xteristics of well controlled asthma1. Daytime snxs not more than 2 days/wk
2. Nocturnal snxs not more than 2 times /mo
3. Use of short acting B-agonist inhaler for snxs control not more than 2 days /wk.
4. Asthma does not interfere w/ normal activity
5. 0 - 1 execration that requires oral systemic corticosteroids per year. - 24Xteristics of well controlled asthma (Lung Fx)FEV1 or PEF =/> 80% predicted or personal best
- 25Xteristic of Not Well Controlled (snxs)1. Daytime snxs > 2 days/week but not daily
2. Nocturmal snxs > 1-3 times/month
3. Use of inhaled short-acting B-agonists for snx control > 2 days/week
4. Some limitations of normal activity =/> 2 exacerbations requiring oral systemic corticosteroids per year. - 26Xteristics of Not Well Controlled (lung fx)FEV1 or PEF 60 - 80% predicted or personal best
- 27Xteristics of Very Poorly Controlled (snx)1. Daily snxs
2. Nocturnal snxs =/> 4x per wk
3. Use ofinhaled, short acting B-agonists several times per day
4. Extreme limitations of normal activity - 28Xteristics of Very Poorly Controlled (lung fxs)FEV1 or PEF < 60% predicted or personal best
- 29Goals of therapy for chronic Asthma is to -----?Require infrequent use (< 2 days/week) of inhaled short-acting β2-agonists for quick relief of symptoms